罗沙司他和rHuEPO在腹膜透析肾性贫血患者中的应用比较

Comparison of Roxastat and rHuEPO in peritoneal dialysis patients with renal anemia

目的:对比分析罗沙司他和重组人红细胞生成素(rHuEPO)在腹膜透析肾性贫血患者中的临床疗效。方法:宁都县人民医院于2021年1月-2023年5月收治的腹膜透析肾性贫血患者65例,通过随机数表分为对照组32例与实验组各33例。两组均予以肾性贫血常规治疗并口服琥珀酸亚铁片。对照组透析结束后注射rHuEPO注射液,实验组结束后口服罗沙司他。治疗结束后评价两组疗效;分别于治疗前与治疗结束2 w后监测患者贫血指标[红细胞计数(RBC)、血红蛋白(Hb)、血清铁蛋白(FER)、血清转铁蛋白(TRF)];记录两组治疗期间头晕、乏力、血压升高、血栓等不良反应发生情况。结果:实验组总有效率为90.91%,显著高于对照组总有效率71.88%,差异有统计意义(P<0.05)。两组患者经治疗后贫血指标(RBC、Hb、TRF、FER)均明显升高,且实验组显著高于对照组(P<0.05)。两组治疗期间头晕、乏力、血压升高、血栓发生率差异无统计意义(P>0.05)。结论:罗沙司他较rHuEPO,对于腹膜透析肾性贫血患者疗效更好、更能改善患者贫血指标,二者均安全可靠,无明显不良反应。

Objective:To compare the clinical efficacy of Roxallistat and recombinant human erythropoietin(rHuEPO)in patients with renal anemia induced by peritoneal dialysis.Methods:65 patients with peritoneal dialysis renal anemia admitted to Ningdu People's Hospital from January 2021 to May 2023 were divided into control group(32 cases)and experimental group(33 cases)by random number table.Both groups were given routine treatment for renal anemia and oral ferrous succinate tablets.The control group was injected with rHuEPO injection after the end of dialysis,and the experimental group was orally administered Roxallistat after the end of dialysis.The curative effect of the two groups was evaluated after treatment.Anemia indicators(red blood cell count(RBC),hemoglobin(Hb),serum ferritin(FER),serum transferrin(TRF))were monitored before treatment and two weeks after treatment.The adverse reactions such as dizziness,fatigue,elevated blood pressure and thrombosis were recorded in the two groups during treatment.Results:The total effective rate of the experimental group was 90.91%,which was significantly higher than that of the control group 71.88%,and the difference was statistically significant(P<0.05).After treatment,the anemia indexes(RBC,Hb,TRF,FER)of the two groups were significantly increased,and the experimental group was significantly higher than the control group(P<0.05).There were no significant differences in the incidence of dizziness,fatigue,elevated blood pressure and thrombosis between the two groups during treatment(P>0.05).Conclusion:Roxalstat is better than rHuEPO in the treatment of renal anemia patients with peritoneal dialysis and can improve the anemia indexes.Both are safe and reliable with no obvious adverse reactions.